Research Article

Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease†

  1. Robert A. Hauser MD1,2,*,
  2. Kelly E. Lyons PhD3,
  3. Terry McClain ARNP1,
  4. Summer Carter MSPH1,
  5. David Perlmutter MD4

Article first published online: 19 FEB 2009

DOI: 10.1002/mds.22401

Issue

Movement Disorders

Movement Disorders

Volume 24, Issue 7, pages 979–983, 15 May 2009

Additional Information

How to Cite

Hauser, R. A., Lyons, K. E., McClain, T., Carter, S. and Perlmutter, D. (2009), Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Mov. Disord., 24: 979–983. doi: 10.1002/mds.22401

Author Information

  1. 1

    Department of Neurology, University of South Florida and Tampa General Healthcare, NPF Center of Excellence, Tampa, Florida

  2. 2

    Department of Molecular Pharmacology and Physiology, University of South Florida and Tampa General Healthcare, NPF Center of Excellence, Tampa, Florida

  3. 3

    Department of Neurology, University of Kansas Medical Center, NPF Center of Excellence, Florida

  4. 4

    Perlmutter Health Center, Naples, Florida

*Parkinson's Disease and Movement Disorders Center, University of South Florida, 5 Tampa General Circle, Suite 410, Tampa, Florida 33606

  1. †

    Potential conflict of interest: All authors have indicated that they have nothing to disclose regarding Wellness Health and Pharmaceuticals or glutathione. Dr. Robert Hauser has received honoraria or consulting fees from Bayer Schering Pharma AG, Bertek, Boehringer Ingelheim, Centopharm, Eisai, Genzyme, GlaxoSmithKline, Impax, Kyowa Pharmaceutical, Merck KgaA, Ortho McNeil, Novartis, Pfizer, Prestwick, Schwarz Pharma, Schering, Solvay, Synosia, Teva Neuroscience, Valeant, and Vernalis. Dr. Kelly Lyons has received honoraria or consulting fees from Advanced Neuromodulation Systems, GlaxoSmithKline, Novartis, Teva Neuroscience, UCB Pharma, and Valeant Pharmaceuticals. Terry McClain has received honoraria or consulting fees from Eisai, GlaxoSmithKline, Kyowa Pharmaceutical, Solvay, Teva Neuroscience, Serono, and Vernalis. Summer Carter has received honoraria or consulting fees from Solvay and Asubio Pharmaceuticals. Dr. David Perlmutter reports nothing to disclose.

Publication History

  1. Issue published online: 28 MAY 2009
  2. Article first published online: 19 FEB 2009
  3. Manuscript Accepted: 24 OCT 2008
  4. Manuscript Revised: 20 AUG 2008
  5. Manuscript Received: 8 JUL 2008

Funded by

  • Wellness Health and Pharmaceuticals (Birmingham, Alabama)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (80K)

Additional Supporting Information may be found in the online version of this article.

FilenameFormatSizeDescription
mds22401supptable1.doc52KSupporting Information Table 1. Baseline medications for each subject.
mds22401supptable2.doc36KSupporting Information Table 2. Means (SD) for UPDRS scores, walking time and tapping for placebo and glutathione groups. P-values represent changes in glutathione vs. changes in placebo from baseline to week 4 (treatment period) and from week 4 to week 12 (no treatment follow-up period).

Please note: Wiley-Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

View Full Article with Supporting Information (HTML) Get PDF (80K)